Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27761093 | 0.95 | SMN1; SMN2 (0.55) | SMN1; SMN2NAAALMNAHTTHPGD | |
| SCHEMBL4341280 | 0.82 | EPHX2 (0.57) | NAAAHTT | |
| SCHEMBL28784043 | 0.78 | POLB (0.56) | SMN1; SMN2NAAAHTTHPGD | |
| SCHEMBL4346806 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAHTT | |
| SCHEMBL13805540 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAHTTHPGDRECQL | |
| SCHEMBL8438232 | 0.77 | LMNA (0.65) | SMN1; SMN2LMNAHTTHPGD | |
| SCHEMBL8391699 | 0.77 | LMNA (0.65) | SMN1; SMN2LMNAHTTHPGD | |
| SCHEMBL8443237 | 0.77 | LMNA (0.65) | SMN1; SMN2LMNAHTTHPGD | |
| SCHEMBL8442878 | 0.77 | LMNA (0.65) | SMN1; SMN2LMNAHTTHPGD | |
| SCHEMBL8439096 | 0.77 | LMNA (0.65) | SMN1; SMN2LMNAHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| CN-1701061-A | Novel compounds for inhibiting rotamase enzymes and uses thereof | JERINI AG (DE) | 2005-11-23 | — | — | CN | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | SMN1; SMN2 1791/4885NAAA 2425/4885LMNA 3160/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | SMN1; SMN2 3250/4885NAAA 2193/4885LMNA 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.